Advanced

Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus

Agardh, Carl-David LU ; Agardh, Elisabet LU ; Andersson, A and Hultberg, Björn LU (1994) In Scandinavian Journal of Clinical & Laboratory Investigation 54(8). p.637-641
Abstract
The reactive vascular-injuring amino acid homocysteine was previously shown to be increased in plasma in diabetic patients with clinical signs of nephropathy. In this study, plasma homocysteine was measured in type 1 diabetic patients with normoalbuminuria (n = 22), microalbuminuria (n = 40) and proteinuria (n = 14) in order to investigate whether plasma homocysteine levels are increased already at the stage of incipient nephropathy, i.e. microalbuminuria. Furthermore, patients were characterized according to the degree of retinopathy. Plasma homocysteine in the whole population (n = 76) was related to B-Folate (r = 0.38, p < 0.01), S-Creatinine (r = 0.55, p < 0.001), S-Urea (r = 0.37, p < 0.01), U-Albumin (r = 0.46, p <... (More)
The reactive vascular-injuring amino acid homocysteine was previously shown to be increased in plasma in diabetic patients with clinical signs of nephropathy. In this study, plasma homocysteine was measured in type 1 diabetic patients with normoalbuminuria (n = 22), microalbuminuria (n = 40) and proteinuria (n = 14) in order to investigate whether plasma homocysteine levels are increased already at the stage of incipient nephropathy, i.e. microalbuminuria. Furthermore, patients were characterized according to the degree of retinopathy. Plasma homocysteine in the whole population (n = 76) was related to B-Folate (r = 0.38, p < 0.01), S-Creatinine (r = 0.55, p < 0.001), S-Urea (r = 0.37, p < 0.01), U-Albumin (r = 0.46, p < 0.001), urinary N-acetyl-beta- glucosaminidase (r = 0.40, p < 0.001), systolic blood pressure (r = 0.36, p < 0.01) and diabetes duration (r = 0.44, p < 0.001). There were no differences in plasma homocysteine levels between patients with normoalbuminuria (8.0 +/- 1.7 mumol l-1; mean +/- SD) and those with microalbuminuria (9.1 +/- 3.4 mumol l-1). However, patients with clinical signs of nephropathy had higher plasma homocysteine levels (12.9 +/- 5.7 mumol l-1, p < 0.01) compared to the other two groups. There was no association between plasma homocysteine levels and different degrees of retinopathy. Thus, the present study does not show any relation between plasma homocysteine levels and early stages of diabetic nephropathy or retinopathy indicating that elevated concentrations of plasma homocysteine does not explain the increased risk for atherosclerosis observed in patients with microalbuminuria. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
nephropathy, retinopathy, homocysteine, diabetes mellitus
in
Scandinavian Journal of Clinical & Laboratory Investigation
volume
54
issue
8
pages
637 - 641
publisher
Informa Healthcare
external identifiers
  • pmid:7709167
  • scopus:0028063645
ISSN
1502-7686
DOI
10.3109/00365519409087544
language
English
LU publication?
yes
id
b163601d-ad7e-4b64-bdc0-d5e0bfe6a28d (old id 1108024)
date added to LUP
2008-07-23 11:28:34
date last changed
2017-08-06 04:33:54
@article{b163601d-ad7e-4b64-bdc0-d5e0bfe6a28d,
  abstract     = {The reactive vascular-injuring amino acid homocysteine was previously shown to be increased in plasma in diabetic patients with clinical signs of nephropathy. In this study, plasma homocysteine was measured in type 1 diabetic patients with normoalbuminuria (n = 22), microalbuminuria (n = 40) and proteinuria (n = 14) in order to investigate whether plasma homocysteine levels are increased already at the stage of incipient nephropathy, i.e. microalbuminuria. Furthermore, patients were characterized according to the degree of retinopathy. Plasma homocysteine in the whole population (n = 76) was related to B-Folate (r = 0.38, p &lt; 0.01), S-Creatinine (r = 0.55, p &lt; 0.001), S-Urea (r = 0.37, p &lt; 0.01), U-Albumin (r = 0.46, p &lt; 0.001), urinary N-acetyl-beta- glucosaminidase (r = 0.40, p &lt; 0.001), systolic blood pressure (r = 0.36, p &lt; 0.01) and diabetes duration (r = 0.44, p &lt; 0.001). There were no differences in plasma homocysteine levels between patients with normoalbuminuria (8.0 +/- 1.7 mumol l-1; mean +/- SD) and those with microalbuminuria (9.1 +/- 3.4 mumol l-1). However, patients with clinical signs of nephropathy had higher plasma homocysteine levels (12.9 +/- 5.7 mumol l-1, p &lt; 0.01) compared to the other two groups. There was no association between plasma homocysteine levels and different degrees of retinopathy. Thus, the present study does not show any relation between plasma homocysteine levels and early stages of diabetic nephropathy or retinopathy indicating that elevated concentrations of plasma homocysteine does not explain the increased risk for atherosclerosis observed in patients with microalbuminuria.},
  author       = {Agardh, Carl-David and Agardh, Elisabet and Andersson, A and Hultberg, Björn},
  issn         = {1502-7686},
  keyword      = {nephropathy,retinopathy,homocysteine,diabetes mellitus},
  language     = {eng},
  number       = {8},
  pages        = {637--641},
  publisher    = {Informa Healthcare},
  series       = {Scandinavian Journal of Clinical & Laboratory Investigation},
  title        = {Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus},
  url          = {http://dx.doi.org/10.3109/00365519409087544},
  volume       = {54},
  year         = {1994},
}